BP
KRYS icon

Ballentine Partners’s Krystal Biotech KRYS Stock Holding History

Ballentine Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$546K Buy
2,115
+7
+0.3% +$1.86K 0.01% 498
2025
Q4 		$520K Sell
2,108
-7
-0.3% -$1.47K 0.01% 490
2025
Q3 		$373K Hold
2,115
– – 0.01% 609
2025
Q2 		$291K Sell
2,115
-21
-1% -$3.08K ﹤0.01% 700
2025
Q1 		$385K Sell
2,136
-9
-0.4% -$1.51K 0.01% 536
2024
Q4 		$336K Buy
2,145
+56
+3% +$9.93K 0.01% 558
2024
Q3 		$380K Hold
2,089
– – 0.01% 505
2024
Q2 		$384K Buy
2,089
+9
+0.4% +$1.51K 0.01% 475
2024
Q1 		$370K Hold
2,080
– – 0.01% 475
2023
Q4 		$258K Hold
2,080
– – 0.01% 550
2023
Q3 		$241K Hold
2,080
– – 0.01% 496
2023
Q2 		$244K Buy
+2,080
New +$212K 0.01% 494

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return